 |
Food and Drug Administration Approval of Use of
Haemophilus b Conjugate Vaccine for Infants
The Food and Drug Administration has approved the
Haemophilus b Conjugate Vaccine (Diphtheria CRM 197 Protein
Conjugate) manufactured by Praxis Biologics, Inc., and
distributed as HibTITERTM by Lederle Laboratories (Pearl River,
New York) for use in infants in a three-dose immunization series
at 2, 4, and 6 months of age. Previously unvaccinated infants
7-11 months of age should receive two doses 2 months apart.
Previously unvaccinated children 12-14 months of age should
receive one dose; a booster dose after 15 months of age is
recommended for these children. Previously unvaccinated children
15-60 months of age should receive a single dose and do not
require a booster.
In the United States, Haemophilus influenzae type b is the
major cause of bacterial meningitis in children less than 5 years
of age, with the peak incidence in children less than 1 year of
age (1). The principal efficacy trial for this vaccine was
conducted in approximately 60,000 infants in the Northern
California Kaiser Permanente Health Plan (2);approximately half
of those children received the vaccine. Twelve cases of H.
influenzae type b invasive disease occurred in unvaccinated
children, compared with no cases in fully vaccinated children,
indicating an efficacy of 100%, with the lower limit of the 95%
confidence interval equal to 68%. The Immunization Practices
Advisory Committee (ACIP) is planning to issue a complete
statement.
Reported by: Center for Biologics Evaluation and Research, Food
and Drug Administration. Center for Infectious Diseases; Center
for Prevention Svcs, CDC.
References
Schlech WF, Ward JI, Band JD, et al. Bacterial meningitis in
the United States, 1978 through 1981: the National Bacterial
Meningitis Surveillance Study. JAMA 1985;253:1749-54. 2. Black
SB, Shinefield HR, Hiatt RA, et al. Efficacy of HbOC conjugate
Haemophilus influenzae type b vaccine in a study population of
48,000 infants (Abstract). In: Program and abstracts of the 30th
Interscience Conference on Antimicrobial Agents and Chemotherapy.
Washington, DC: American Society for Microbiology, 1990.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov. Page converted: 08/05/98
|
|
